Recommendations alone will not avert a liver disease epidemic.

The Federal Government needs to list new hepatitis C medicines on the Pharmaceutical Benefits Scheme (PBS) without further delay, according to the peak body representing the interests of a quarter of a million Australians living with the liver-destroying virus.


Responding to the latest round of Pharmaceutical Benefits Advisory Committee recommendations, Hepatitis Australia CEO Helen Tyrrell said a total of four groundbreaking curative hepatitis C therapies have now received the green light for inclusion on the PBS but so far no listing date has been confirmed.

Read More